CompletedPhase 3

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

United States37 participantsStarted 2020-06-11

Plain-language summary

This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment * Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months Exclusion Criteria: * Current or anticipated enrollment in another investigational drug or device study * Females who are pregnant, nursing, or planning a pregnancy during the study

What they're measuring

Change From Baseline in Time-Matched Intraocular Pressure (IOP) for Bimatoprost SR Treated Eyes

Timeframe: 8 weeks

Number of Patients Experiencing One or More Treatment Emergent Adverse Events (TEAEs)

Timeframe: Up to 12 Months

Trial details

NCT IDNCT04285580

SponsorAbbVie

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-05-14

Results submitted2023-05-12

View on ClinicalTrials.gov More Open-Angle Glaucoma trials